Browse News

Found 42,736 articles

• Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response

  3/29/2023

  Genialis announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.

• Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer

  3/29/2023

  Transcenta Holding Limited announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Osemitamab, its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, for the treatment of patients with pancreatic cancer.

• 

  BioSpace Layoff Tracker 2023: Applied Molecular Transport, Evofem, Amgen, and More Cut Staff

  3/28/2023

  Follow along as BioSpace keeps you up-to-date on which companies are tightening their belts and cutting staff throughout 2023.  

• Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients

  3/28/2023

  Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program.

• Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board

  3/28/2023

  Eterna Therapeutics Inc., a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, announced the appointment of Jeff Karp, Ph.D. to Eterna’s Scientific Advisory Board.

• CereVasc Appoints Dr. Adel Malek Chief Medical Officer

  3/28/2023

  CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, names Adel Malek, MD PhD as the company's Chief Medical Officer.

• Cellino Chief Operating Officer Dr. Abhijit Kulkarni Inducted Into AIMBE’s 2023 College of Fellows

  3/28/2023

  Cellino Biotech, Inc. announced that Chief Operating Officer Abhijit Kulkarni, Ph.D., was inducted to The American Institute for Medical and Biological Engineering College of Fellows.

• Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Receives Entrepreneur Distinction from The University System of Georgia Board of Regents

  3/28/2023

  Aruna Bio, Inc. announced that the Company’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, has been named one of the first recipients of Entrepreneur Distinction from The University System of Georgia Board of Regents.

• Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

  3/28/2023

  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for full-year 2022 and provided recent business updates.

• Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test

  3/28/2023

  SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay.

• Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates

  3/28/2023

  Bicycle Therapeutics plc today announced that it has entered into a strategic collaboration agreement with Novartis to develop, manufacture and commercialize Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets.

• Gelesis Reports Fourth Quarter and Full Year 2022 Results

  3/28/2023

  Gelesis Holdings, Inc. today reported financial results for the year ended December 31, 2022.

• Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck

  3/28/2023

  Ratio Therapeutics Inc. (Ratio) today announced the licensing of a Granzyme B-targeted agent for PET imaging applications from Merck, known as MSD outside the United States and Canada.

• Andrew Miller Joints Elucid as Chief Technology Officer

  3/28/2023

  Elucid, Inc. has hired Andrew Miller as its chief technology officer (CTO).

• Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396

  3/28/2023

  Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced Phase 1a results for ZP8396, the company’s amylin analogue.

• CureVac Announces Voting Results of Extraordinary General Meeting

  3/28/2023

  CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the voting results of the Company's extraordinary general meeting.

• Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days

  3/28/2023

  Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 9:00 a.m. E.T in New York, NY.

• Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies

  3/28/2023

  Allarity Therapeutics, Inc. announced updates to its ongoing phase 2 clinical programs evaluating IXEMPRA® and stenoparib as monotherapies.

• GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results

  3/28/2023

  GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today reported operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.

• Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

  3/28/2023

  Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the fourth quarter and full-year 2022 and summarized recent business highlights.